News Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 06/03/2026 GMT			5-day change	1st Jan Change
60.29 ^USD	-0.74%		-3.33%	+11.77%

03-07	Bristol Myers Squibb Receives U.S. FDA Approval For Sotyktu For Treatment Of Adults With Active Psoriatic Arthritis	CI
03-06	Novartis Shareholders Approve Dividend Raise, Share Capital Reduction	MT

All News

03-07	Bristol Myers Squibb Receives U.S. FDA Approval For Sotyktu For Treatment Of Adults With Active Psoriatic Arthritis	CI
03-07	U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis	BU
03-06	Novartis Shareholders Approve Dividend Raise, Share Capital Reduction	MT
03-06	Novartis Shareholders Re-elect Board Chair	MT
03-04	Murray International Trust eyes continued global growth as ups payout	AN
03-02	Bristol-Myers Squibb Keeps Quarterly Dividend at $0.63 a Share, Payable May 1 to Shareholders of Record on April 2	MT
03-02	Bristol Myers Squibb announces dividend	RE
03-02	Bristol Myers Squibb Announces Dividend	BU
03-02	Bristol Myers Squibb Declares Quarterly Dividend, Payable on May 1, 2026	CI
03-02	Bristol-Myers Squibb Company Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 09:50 AM
02-26	SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer	BU
02-25	Bristol-Myers Squibb's Risk/Reward Profile Balanced, RBC Says	MT
02-25	RBC Initiates Bristol-Myers Squibb at Sector Perform With $60 Price Target	MT
02-25	Berenberg Lifts Price Target on Bristol-Myers Squibb to $60 From $57, Keeps Hold Rating	MT
02-23	Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference	BU
02-23	Piper Sandler Adjusts Price Target on Bristol-Myers Squibb to $75 From $66, Maintains Overweight Rating	MT
02-23	Bristol-Myers Says Reblozyl Treatment Shows Significant Improvement in Thalassemia Patients	MT
02-23	Bristol Myers Squibb announces positive top-line results from registrational phase 2 study of luspatercept	RE
02-23	Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia	BU
02-23	Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha-Thalassemia	CI
02-20	US FDA approves Vanda's antipsychotic pill, shares climb	RE
02-20	Daiwa Securities Adjusts Price Target on Bristol-Myers Squibb to $62 From $43, Maintains Neutral Rating	MT
02-20	Inflation's Reality Check
02-20	Analyst recommendations: Walmart, Alphabet, Deere & Company, Stellantis, Workday…
02-19	Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions	RE